| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Section of Pulmonary and Critical Care Medicine, Depts of Medicine, Neurobiology Pharmacology and Physiology, Pediatrics, Anesthesia and Critical Care, and Committees on 2 Clinical Pharmacology and Pharmacogenomics, 3 Cell Physiology and Molecular Medicine, Division of the Biological Sciences, The University of Chicago, Chicago, USA
CORRESPONDENCE: A.R. Leff, Section of Pulmonary and Critical Care Medicine, Department of Medicine, MC6076, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA. Fax: 1 7737029181. E-mail: aleff@medicine.bsd.uchicago.edu
Keywords: Adhesion Molecules, ß2-agonists, eosinophils, fluticasone propionate, glucocorticoids, salmeterol
Received: June 11, 2003
Accepted November 27, 2003
This work was supported by National Heart, Lung, and Blood Institute (NHLBI) Grant HL-46368, NHLBI SCOR Grant HL-56399 (A.R. Leff) and AI-52109 (X. Zhu), and GlaxoSmithKline, Research Triangle Park, NC, USA.
Migration of human eosinophils is regulated by integrin expression, conformational change, and activation of cytosolic phospholipase A2 (cPLA2). Corticosteroids have been shown to inhibit cPLA2 hydrolysis in human eosinophils. The objective of this study was to determine the mechanisms of fluticasone propionate (FP) alone or in combination with salmeterol (SM) in blocking adhesion mediated by ß2-integrin in human eosinophils.
Human eosinophils were isolated by negative magnetic selection. ß2-integrin-mediated eosinophil adhesion was measured by residual eosinophil peroxidase activity. Eosinophils were pretreated for 12 h to 24 h with FP and with or without SM for 30 min.
Both SM alone and FP alone inhibited eosinophil adhesion in concentration- and time-dependent manner. SM alone modestly (
Blockade of ß2-integrin-mediated eosinophil adhesion by fluticasone propionate is augmented by salmeterol. Decreased adhesion results from augmented blockade of nuclear translocation of cytosolic phospholipase A2 caused by addition of salmeterol to fluticasone.
30%) inhibited interleukin (IL)-5-induced eosinophil adhesion. Blockade of IL-5-induced eosinophil adhesion caused by 10–7 M FP at 24 h was augmented by 10–7 M SM from 41.5% to 72.5%. Similar blockade was also observed for eotaxin-induced eosinophil adhesion. Neither SM, FP, nor FP+SM blocked either: 1) upregulation of CD11b surface expression; or 2) phosphorylation of cPLA2.
This article has been cited by other articles:
|
|
 |
|
  A. Y. Meliton, N. M. Munoz, X. Zhu, and A. R. Leff Attenuated translocation of group IVa phospholipase A2 and up-regulated annexin-1 synthesis by glucocorticoid blocks {beta}2-integrin adhesion in neutrophils J. Leukoc. Biol., February 1, 2008; 83(2): 344 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Leff and N. M. Munoz Future Treatment to Lessen Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Meliton, N. M. Munoz, A. Lambertino, E. Boetticher, J. Learoyd, X. Zhu, and A. R. Leff Phosphodiesterase 4 inhibition of {beta}2-integrin adhesion caused by leukotriene B4 and TNF-{alpha} in human neutrophils Eur. Respir. J., November 1, 2006; 28(5): 920 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. ten Hove, L. A. Houben, J. A. M. Raaijmakers, L. Koenderman, and M. Bracke Rapid Selective Priming of Fc{alpha}R on Eosinophils by Corticosteroids J. Immunol., November 1, 2006; 177(9): 6108 - 6114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.P. Hart Additive blockade of {beta}2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate Eur. Respir. J., August 1, 2004; 24(2): 333 - 333. [Full Text] [PDF]
|
|
|
|
|
|
A.R. Leff From the Authors Eur. Respir. J., August 1, 2004; 24(2): 334 - 334. [Full Text] [PDF]
|
|
|
|
|
|
A. Papi Investigating the steroids and long-acting {beta}2-agonists combination: why do we need more? Eur. Respir. J., April 1, 2004; 23(4): 501 - 502. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
